Drager Medizintechnik GmbH and Masimo Corporation

Announce Pulse Oximetry Purchasing and Licensing Agreement IRVINE, Calif. (PROTEXT) - Drager Medizintechnik GmbH (Lübek,Germany) and Masimo Corporation (Irvine, CA) announced apurchasing and licensing agreement under which Drager willintegrate Masimo Signal Extraction pulse oximetry technology intoits future patient monitors which incorporate pulse oximetry. Drager Medizintechnik GmbH is a leading manufacturer ofmedical equipment worldwide. Drager has earned a reputation ofexcellence in both product design and customer support. Masimo Signal Extraction pulse oximetry is the only technologyclinically proven accurate during patient motion and lowperfusion. Numerous published studies have shown a virtualelimination of false alarms without sacrificing the ability todetect true alarms with Masimo Signal Extraction pulse oximetry,as compared with the other leading pulse oximetry systems. "During Drager's long history, we have made one commitment toour customers, and that is to provide them with the besttechnology possible," stated Frank Rochlitzer, President ofDrager Medizintechnik GmbH. "We spent considerable timeevaluating the performance of Masimo SET pulse oximetry andconcluded that Masimo SET pulse oximetry would be an ideal choicefor our future monitors and our customers." Joe E. Kiani, President and Chief Executive Officer of MasimoCorporation, stated, "Drager is widely recognized as one of thepremier providers of medical equipment in the world. Just abouteverything they sell is considered best in its class and mostpeople in the industry recognize Drager as being synonymous withquality. After working with Drager, I now understand how theyachieved such a reputation. Their team is as solid a group ofprofessionals that we have had the pleasure to work with. We aredelighted to have Drager as a partner." Masimo Corporation is a privately-held medical technologycompany that designs, develops and licenses advanced medicalsignal processing and sensor technology for the noninvasivemonitoring of vital physiological parameters. Masimo has createda fundamentally unique method to measure arterial oxygensaturation and pulse rate. Masimo Signal Extraction pulseoximetry is the only technology clinically proven accurate duringpatient motion and low perfusion. Masimo has licensed its SignalExtraction pulse oximetry OEM boards and proprietary singlepatient adhesive and reusable sensors to more than 25international patient monitoring system providers. Masimo islocated in Irvine, California. ots Original Text Service: MasimoCorporation Internet: http://www.newsaktuell.de Contact: BradLangdale of Masimo Corporation, 949-253-6404 Web site:http://www.masimo.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT